- Supported exchanges /
- F /
- 63V.F
VERICI DX PLC LS-001 (63V F) stock market data APIs
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.
VERICI DX PLC LS-001 Financial Data Overview
| 0.0385 | |
| 0.04 | |
| - | |
| 0.04 | |
| 0.0385 | |
| 0.0385-0.138 | |
| 10 174 K | |
| 243 M | |
| 4 333 K | |
| 1.591 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
VERICI DX PLC LS-001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 4 333 K
- EBITDA -3 742 000
- Earnings Per Share -0.02
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get VERICI DX PLC LS-001 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get VERICI DX PLC LS-001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
